JG
CLVS

Joel Greenblatt’s Clovis Oncology, Inc. CLVS Stock Holding History

Joel Greenblatt’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-146,799
Closed -$1.53M – 1249
2019
Q4 		$1.53M Buy
+146,799
New +$1.07M 0.03% 529
2017
Q3 		– Sell
-3,727
Closed -$349K – 1079
2017
Q2 		$349K Buy
+3,727
New +$228K ﹤0.01% 811

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Joel Greenblatt's CLVS Position: Q1 2020 in Review

Joel Greenblatt sold out of Clovis Oncology, Inc. (CLVS) in Q1 2020, closing a stake of 146,799 shares — an estimated $1.53M sold.

Joel Greenblatt first reported a position in CLVS in Q2 2017 and held it in 2 quarters. The position peaked at $1.53M in Q4 2019. 154 funds tracked by Wall St. Rank hold CLVS as of Q1 2020.

  • Joel Greenblatt reported no remaining Clovis Oncology, Inc. position as of Q1 2020 after selling out during the quarter.
  • Joel Greenblatt sold 146,799 Clovis Oncology, Inc. shares in Q1 2020, an estimated $1.53M.
  • Joel Greenblatt first reported a position in Clovis Oncology, Inc. in Q2 2017 and held it in 2 quarters.
  • Joel Greenblatt's Clovis Oncology, Inc. position peaked at $1.53M in Q4 2019.
  • 154 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2020.

Based on Gotham Asset Management's 13F filing for Q1 2020, filed 15 May 2020.